Status:
RECRUITING
The Dynamics of Human Atrial Fibrillation
Lead Sponsor:
Stanford University
Conditions:
Atrial Fibrillation
Arrhythmias, Cardiac
Eligibility:
All Genders
22-80 years
Brief Summary
Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the ...
Detailed Description
The specific aim of this clinical study is to identify patients who will or will not respond to PVI, PVI plus other ablation or Maze surgery based on locations of organized-to-disorganized areas and c...
Eligibility Criteria
Inclusion
- referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and/or lasts \>7 days)
- Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of \>or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation.
Exclusion
- active coronary ischemia or decompensated heart failure
- atrial or ventricular clot on trans-esophageal echocardiography
- pregnancy (to minimize fluoroscopic exposure)
- inability or unwillingness to provide informed consent
- rheumatic valve disease (results in a unique AF phenotype)
- thrombotic disease or venous filters
- prior chest surgery is a relative contraindication for Maze surgery
Key Trial Info
Start Date :
August 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05366361
Start Date
August 18 2020
End Date
December 30 2026
Last Update
December 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305